Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 5Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Lung Neoplasms 78Neoplasms 37Mesothelioma 23Mesothelioma, Malignant 21Neoplasm Metastasis 20Breast Neoplasms 18Adenocarcinoma of Lung 18Head and Neck Neoplasms 13Colorectal Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 11Ovarian Neoplasms 11Carcinoma 8Uterine Cervical Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Adenocarcinoma, Bronchiolo-Alveolar 6Adenocarcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Meningeal Carcinomatosis 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Recurrence 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Laryngeal Diseases 4Endometrial Neoplasms 4

Interventions

entinostat 3pembrolizumab 2osimertinib 2Gefitinib 2Erlotinib Hydrochloride 2sotorasib 1pralsetinib 1ficlatuzumab 1exemestane 1efineptakin alfa 1durvalumab 1cobimetinib 1camrelizumab 1Tyrosine Kinase Inhibitors 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Proton Therapy 1Pemetrexed 1Magnetic Resonance Imaging 1Intubation 1Injections, Epidural 1Electrocardiography 1Echocardiography 1Dasatinib 1Carboplatin 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thoracic Neoplasms × Pemetrexed × Clear all
NCT03134872 2020-06-09

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
419 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡